Oric Pharmaceuticals Inc (ORIC)

Jan 13, 2025, 8:05 AM EST - 4 days ago

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

Jan 6, 2025, 4:15 PM EST - 11 days ago

ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 4:30 PM EST - 14 days ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Nov 25, 2024, 4:15 PM EST - 7 weeks ago

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

Nov 1, 2024, 4:30 PM EDT - 2 months ago

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Oct 9, 2024, 4:15 PM EDT - 3 months ago

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 4, 2024, 4:30 PM EDT - 3 months ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aug 26, 2024, 4:05 PM EDT - 5 months ago

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 12, 2024, 4:05 PM EDT - 5 months ago

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

Aug 5, 2024, 4:15 PM EDT - 5 months ago

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

Jul 17, 2024, 1:00 PM EDT - 6 months ago

ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value

Jul 16, 2024, 4:59 PM EDT - 6 months ago

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

May 6, 2024, 4:05 PM EDT - 9 months ago

ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

Apr 15, 2024, 4:15 PM EDT - 9 months ago

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

Apr 8, 2024, 8:00 AM EDT - 10 months ago

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 13, 2024, 8:19 AM EDT - 11 months ago

ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains

Mar 11, 2024, 4:05 PM EDT - 11 months ago

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates

Mar 6, 2024, 4:30 PM EST - 11 months ago

ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 4:30 PM EST - 11 months ago

ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Feb 14, 2024, 4:30 PM EST - 1 year ago

ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit

Jan 22, 2024, 8:30 AM EST - 1 year ago

ORIC Pharmaceuticals Announces $125 Million Private Placement Financing

Jan 8, 2024, 8:30 AM EST - 1 year ago

ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones

Jan 2, 2024, 4:30 PM EST - 1 year ago

ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 11, 2023, 12:00 PM EST - 1 year ago

Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development

Dec 9, 2023, 8:00 AM EST - 1 year ago

ORIC Pharma NSCLC Brain Metastasis Data Is Highly Interesting

Nov 6, 2023, 4:10 PM EST - 1 year ago

ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

Nov 2, 2023, 9:00 AM EDT - 1 year ago

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

Oct 21, 2023, 7:30 AM EDT - 1 year ago

Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

Oct 17, 2023, 4:30 PM EDT - 1 year ago

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023

Sep 20, 2023, 4:30 PM EDT - 1 year ago

ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference

Aug 10, 2023, 4:05 PM EDT - 1 year ago

ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates

Jul 27, 2023, 3:57 PM EDT - 1 year ago

You can still run with the stock market's bulls, but watch the exits

CCL CRON EEM EW KOPN PFG PRU

Jun 26, 2023, 8:30 AM EDT - 1 year ago

ORIC Pharmaceuticals Announces $85 Million Private Placement Financing

May 31, 2023, 4:10 PM EDT - 1 year ago

ORIC Pharmaceuticals to Participate in the Jefferies Healthcare Conference

May 8, 2023, 4:05 PM EDT - 1 year ago

ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

Apr 25, 2023, 4:30 PM EDT - 1 year ago

ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference

Apr 18, 2023, 4:15 PM EDT - 1 year ago

ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Mar 16, 2023, 4:05 PM EDT - 2 years ago

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates

Mar 15, 2023, 12:47 AM EDT - 2 years ago

ORIC Pharma: Small Pfizer Deal, Cash, And A Set Of Very Early Stage Assets

Mar 14, 2023, 4:30 PM EDT - 2 years ago

ORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Mar 6, 2023, 4:15 PM EST - 2 years ago

ORIC Pharmaceuticals to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Jan 9, 2023, 8:00 AM EST - 2 years ago

ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones

Jan 3, 2023, 4:30 PM EST - 2 years ago

ORIC Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 22, 2022, 8:38 AM EST - 2 years ago

Oric's stock rallies on multiple myeloma deal with Pfizer

PFE

Dec 21, 2022, 5:48 PM EST - 2 years ago

ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer

Dec 13, 2022, 8:00 AM EST - 2 years ago

ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting

Nov 8, 2022, 4:10 PM EST - 2 years ago

ORIC Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Nov 7, 2022, 4:05 PM EST - 2 years ago

ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update

Nov 3, 2022, 9:00 AM EDT - 2 years ago

ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple Myeloma at the 64th American Society of Hematology (ASH) Annual Meeting

Oct 14, 2022, 9:43 AM EDT - 2 years ago

ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech